Expression of steroid hormone receptors (HRs) in cancer cells justifies the introduction of endocrine therapies (ET), e.g., selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or selective estrogen receptor degraders (SERDs) [1]. The gene discussed is ESR1; the disease is cancer.